New glaucoma testing device praised

Article

The TrueField Analyser, a glaucoma testing device, has been hailed by reseachers at the Australian National University as offering faster, more comprehensive and more accurate diagnoses than current methods.

The TrueField Analyser, a glaucoma testing device, has been hailed by researchers at the Australian National University as offering faster, more comprehensive and more accurate diagnoses than current methods.

The heads of research, Dr Andrew James and Ted Maddess, who developed the device in collaboration with Seeing Machines Ltd, explained how the multifocal pupillographic perimetry produces a more consistent result by measuring pupil responses to just 88 visual stimuli; the device also makes measurements for both eyes simultaneously, and monitors these on a video camera system. These modifications to the traditional testing method produce a faster, objective and reproducible image, and also produce information on the brain and retinal function.

The researchers presented the results of a study demonstrating the commercial viability of the TrueField Analyser at the 29th annual Australian Neuroscience Society held in Canberra in January. Seeing Machines Ltd anticipates the device will be available by the middle of the year.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.